Your fact-checks will appear here
The safety and risks associated with tirzepatide, an active ingredient in the injectable prescription product Lipoless.
Clinical trials and pooled analyses consistently identify gastrointestinal effects — especially nausea, diarrhea, vomiting and constipation — as the most common adverse reactions to tirzepatide, while...
Two different products are being reported under similar names: over-the-counter fiber supplements built on glucomannan (often marketed as “Lipozene”-style products) and an injectable, prescription pro...
Tirzepatide — a dual GIP and GLP‑1 receptor agonist — produces larger average weight losses in randomized trials than single‑receptor GLP‑1 drugs such as semaglutide and liraglutide, with dose‑depende...